Daniel D. Burton - Dec 7, 2021 Form 4 Insider Report for Health Catalyst, Inc. (HCAT)

Role: Chief Executive Officer, Director
Signature: /s/ Daniel Orenstein, as Attorney-in-Fact
Stock symbol: HCAT
Transactions as of: Dec 7, 2021
Transactions value $: -$460,764
Form type: 4
Date filed: 12/9/2021, 05:42 PM
Previous filing: Dec 7, 2021
Next filing: Feb 28, 2022

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	HCAT	Common Stock	Options Exercise	$168K	+15.5K	+6.56%	$10.80	252K	Dec 7, 2021	Direct
transaction	HCAT	Common Stock	Sale	-$628K	-15.5K	-6.15%	$40.47	237K	Dec 7, 2021	Direct	F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	HCAT	Stock Option (Right to Buy)	Options Exercise	$0	-15.5K	-8.96%	$0.00	158K	Dec 7, 2021	Common Stock	15.5K	$10.80	Direct	F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The sale reported on this Form 4 was made pursuant to a written trading plan adopted by the Reporting Person on March 4, 2021, in accordance with Rule 10b5-1.
F2	Represents the weighted average sale price of the shares sold ranging from $40.14 to $40.75 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this Footnote.
F3	25% of the 747,223 shares underlying the option vested in an annual installment on September 25, 2019 and the remaining balance vested or will vest in equal monthly installments until the option vests in full on September 25, 2022.